Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The objective of this US-based retrospective cohort study is to evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
Subjects will be aged 12 years and older and will have no evidence of prior SARS-CoV-2 infection.
The primary analysis will be conducted on subjects vaccinated with BNT162b2.
A variety of subgroup analyses and sensitivity analyses are planned.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Unique enrollees in the HealthVerity Vaccine dataset anytime after December 10, 2020
2. At least 12 years on the index date (ie, first vaccination date)
3. No evidence of prior COVID-19 infection (a medical claim, pharmacy claim, or chargemaster record with a diagnosis code of ICD-10-CM U07.1) in the 12 months prior to the index date
4. Have 12 months of continuous enrollment with medical benefits (with or without pharmacy benefits) prior to the index date.
Subjects with an IC condition will be identified via an algorithm developed for use in administrative claims database studies.
Clareo Health | COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
